Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome

Journal of Hematotherapy and Stem Cell Research

Volumn 6, Issue 5, 1997, Pages 441-446

  Bishop, Michael R ^a,b   Jackson, John D ^a   Tarantolo, Stefano R ^a   O'Kane Murphy, Barbara ^b   Iversen, Patrick L ^a   Bayever, Eliel ^a   Joshi, Shantaram M ^b   Sharp, J Graham ^b   Pierson, Jene L ^a   Warkentin, Phyllis I ^a   Armitage, James O ^a   Kessinger, Anne ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN P53; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CELL SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION;

ADULT; BONE MARROW PURGING; BONE MARROW TRANSPLANTATION; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OLIGONUCLEOTIDES, ANTISENSE; PILOT PROJECTS; THIONUCLEOTIDES; TRANSPLANTATION, AUTOLOGOUS;

EID: 0030828589     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Cheson, B.D., Lacerna, L., Leyland-Jones, B., et al. Autologous bone marrow transplantation: Current status and future directions. Ann. Intern. Med. 110:51, 1989.
2. Brenner, M.K., Rill, D.R., Moen, R.C., et al. Gene marking to trace the origin of relapse after autologous bone marrow transplantation. Lancet 341:85, 1993.
3. Gorin, N.C., Aegerter, P., Auvert, B., et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: A European survey of the role of marrow purging. Blood 75:1606, 1990.
4. Miller, C.A., Rowlings, P.A., Jones, R.J., et al. Autotransplants for acute myelogenous leukemia (AML): Effect of purging with 4-hydroperoxycyclophosphamide (4HC). Blood 86 (Suppl. 1):100a (abstract), 1995.
5. Busca, A., Anasetti, C., Anderson, G., et al. Unrelated donor or autologous marrow transplantation for treatment of acute leukemia. Blood 83:3077, 1994.
6. Gewirtz, A.M. Bone marrow purging with antisense oligodeoxynucleotides. In Advances in Bone Marrow Purging and Processing, eds. Worthington-White, D.A., Gee, A.P. & Gross, S. Wiley-Liss, New York, 1992, p. 215.
7. Kirkland, M.A., O'Brien, S.G., McDonald, C., et al. Antisense purging in chronic myelogenous leukemia [letter]. Lancet 342:614, 1993.
8. Cline, M.J. The molecular basis of leukemia. N. Engl. J. Med. 330:328, 1994.
9. Smith, L.J., McCulloch, E.A. & Benchimol, S. Expression of the p53 oncogene in acute myeloblastic leukemia. J. Exp. Med. 164:751, 1986.
10. Kastan M.B., Radin, A.I., Kuerbitz, S.J., et al. Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res. 51:4279, 1991.
11. Bayever, E., Haines, K.M., Iversen, P.L., et al. Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences. Leukemia Lymphoma 12:223, 1994.
12. Iversen, P.L., Copple, B.L. & Tewary, H.K. Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man. Toxicol. Lett. 82/83:425, 1995.
13. Bishop, M.R., Iversen, P.L., Bayever, E., et al. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J. Clin. Oncol. 14:1320, 1996.
14. Ma, D.D.F. & Doan, T.L. Antisense oligonucleotides therapies: Are they the "magic bullets"? Ann. Intern. Med. 120:161, 1994.
15. Bishop, M.R., Warkentin, P.I., Jackson, J.D., et al. Antisense oligonucleotide OL(1)p53 for in vitro purging of autologous bone marrow in acute myelogenous leukemia. In Progress in Clinical and Biological Research, eds. Worthington-White, D.A., Gee, A.P. & Gross, S. Wiley-Liss, New York, 1994, p. 183.
16. Maciejewski, J.P., Liu, J.M., Green, S.W., et al. Expression of stem cell inhibitor (SCI) gene in patients with bone marrow failure. Exp. Hematol. 20:1112, 1992.
17. Liozon, E., Pradelles, P., Venot, J., et al. Serum levels of a negative regulator of cell proliferation (AcSDKP) are increased in certain human haemopathies. Leukemia 7:808, 1993.
18. Liozon, E., Volkov, L., Comte, L., et al. AcSDKP serum concentrations vary during chemotherapy in patients with acute myeloid leukemia. Br. J. Haematol. 89:917, 1995.
19. Bayever, E., Haines, K.M., Gopple, B.L., et al. Interactions between antisense oligonucleotides to p53 mRNA and reactive oxygen in acute myelogenous leukemia. Proc. Am. Assoc. Cancer Res. 36:411 (abstract), 1995.